ALDEYRA THERAPEUTICS INC (ALDX) Stock Price, Forecast & Analysis
USA - NASDAQ:ALDX - US01438T1060 - Common Stock
ALDX Key Statistics, Chart & Performance
The current stock price of ALDX is 5.02 USD. In the past month the price decreased by -6.86%. In the past year, price increased by 19.24%.
ALDX Latest News, Press Relases and Analysis
ALDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.58 | 410.35B | ||
| AMGN | AMGEN INC | 15.36 | 180.89B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.44 | 73.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.14 | 59.51B | ||
| INSM | INSMED INC | N/A | 40.36B | ||
| NTRA | NATERA INC | N/A | 27.54B | ||
| BIIB | BIOGEN INC | 9.84 | 24.15B | ||
| INCY | INCYTE CORP | 16.42 | 20.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.52 | 20.91B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.49 | 14.30B |
Related stock screener links
About ALDX
Company Profile
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Company Info
ALDEYRA THERAPEUTICS INC
131 Hartwell Avenue, Suite 320
Lexington MASSACHUSETTS 02421 US
CEO: Todd C. Brady
Employees: 9
Phone: 17817614904
ALDEYRA THERAPEUTICS INC / ALDX FAQ
What does ALDX do?
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
What is the current price of ALDX stock?
The current stock price of ALDX is 5.02 USD. The price decreased by -5.28% in the last trading session.
Does ALDX stock pay dividends?
ALDX does not pay a dividend.
What is the ChartMill rating of ALDEYRA THERAPEUTICS INC stock?
ALDX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of ALDEYRA THERAPEUTICS INC (ALDX)?
ALDEYRA THERAPEUTICS INC (ALDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
When does ALDEYRA THERAPEUTICS INC (ALDX) report earnings?
ALDEYRA THERAPEUTICS INC (ALDX) will report earnings on 2026-02-26, after the market close.
What is the Short Interest ratio of ALDEYRA THERAPEUTICS INC (ALDX) stock?
The outstanding short interest for ALDEYRA THERAPEUTICS INC (ALDX) is 8.67% of its float.
ALDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALDX. When comparing the yearly performance of all stocks, ALDX turns out to be only a medium performer in the overall market: it outperformed 63.5% of all stocks.
ALDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALDX. ALDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALDX Financial Highlights
Over the last trailing twelve months ALDX reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 2.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.52% | ||
| ROE | -87.71% | ||
| Debt/Equity | 0 |
ALDX Forecast & Estimates
12 analysts have analysed ALDX and the average price target is 9.86 USD. This implies a price increase of 96.41% is expected in the next year compared to the current price of 5.02.